Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

Individual Amino Acid Supplementation Can Improve Energy Metabolism and Decrease ROS Production in Neuronal Cells Overexpressing Alpha-Synuclein.

Delic V, Griffin JWD, Zivkovic S, Zhang Y, Phan TA, Gong H, Chaput D, Reynes C, Dinh VB, Cruz J, Cvitkovic E, Placides D, Frederic E, Mirzaei H, Stevens SM Jr, Jinwal U, Lee DC, Bradshaw PC.

Neuromolecular Med. 2017 Sep;19(2-3):322-344. doi: 10.1007/s12017-017-8448-8. Epub 2017 Jun 15.

PMID:
28620826
2.

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.

Vázquez R, Riveiro ME, Astorgues-Xerri L, Odore E, Rezai K, Erba E, Panini N, Rinaldi A, Kwee I, Beltrame L, Bekradda M, Cvitkovic E, Bertoni F, Frapolli R, D'Incalci M.

Oncotarget. 2017 Jan 31;8(5):7598-7613. doi: 10.18632/oncotarget.13814.

3.

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.

Riveiro ME, Astorgues-Xerri L, Vazquez R, Frapolli R, Kwee I, Rinaldi A, Odore E, Rezai K, Bekradda M, Inghirami G, D'Incalci M, Noel K, Cvitkovic E, Raymond E, Bertoni F.

Oncotarget. 2016 Dec 20;7(51):84675-84687. doi: 10.18632/oncotarget.13181.

4.

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.

Boi M, Todaro M, Vurchio V, Yang SN, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M, Cerchietti L, Elemento O, Riveiro ME, Cvitkovic E, Bertoni F, Inghirami G; AIRC 5xMille Consortium ‘Genetics-Driven Targeted Management of Lymphoid Malignancies’.

Oncotarget. 2016 Nov 29;7(48):79637-79653. doi: 10.18632/oncotarget.12876.

5.

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.

Vázquez R, Licandro SA, Astorgues-Xerri L, Lettera E, Panini N, Romano M, Erba E, Ubezio P, Bello E, Libener R, Orecchia S, Grosso F, Riveiro ME, Cvitkovic E, Bekradda M, D'Incalci M, Frapolli R.

Int J Cancer. 2017 Jan 1;140(1):197-207. doi: 10.1002/ijc.30412. Epub 2016 Sep 19.

6.

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.

Gaudio E, Tarantelli C, Ponzoni M, Odore E, Rezai K, Bernasconi E, Cascione L, Rinaldi A, Stathis A, Riveiro E, Cvitkovic E, Zucca E, Bertoni F.

Oncotarget. 2016 Sep 6;7(36):58142-58147. doi: 10.18632/oncotarget.10983.

7.

OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.

Berenguer-Daizé C, Astorgues-Xerri L, Odore E, Cayol M, Cvitkovic E, Noel K, Bekradda M, MacKenzie S, Rezai K, Lokiec F, Riveiro ME, Ouafik L.

Int J Cancer. 2016 Nov 1;139(9):2047-55. doi: 10.1002/ijc.30256. Epub 2016 Jul 30.

8.

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.

Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, Schäfers S, Bell E, Nortmeyer M, Westermann F, De Preter K, Florin A, Heukamp L, Spruessel A, Astrahanseff K, Lindner S, Sadowski N, Schramm A, Astorgues-Xerri L, Riveiro ME, Eggert A, Cvitkovic E, Schulte JH.

Clin Cancer Res. 2016 May 15;22(10):2470-81. doi: 10.1158/1078-0432.CCR-15-1449. Epub 2015 Dec 2.

9.

Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.

Odore E, Lokiec F, Cvitkovic E, Bekradda M, Herait P, Bourdel F, Kahatt C, Raffoux E, Stathis A, Thieblemont C, Quesnel B, Cunningham D, Riveiro ME, Rezaï K.

Clin Pharmacokinet. 2016 Mar;55(3):397-405. doi: 10.1007/s40262-015-0327-6.

PMID:
26341814
10.

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.

Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, Rinaldi A, Testoni M, Cascione L, Ponzoni M, Mensah AA, Stathis A, Stussi G, Riveiro ME, Herait P, Inghirami G, Cvitkovic E, Zucca E, Bertoni F.

Clin Cancer Res. 2015 Apr 1;21(7):1628-38. doi: 10.1158/1078-0432.CCR-14-1561. Epub 2015 Jan 26.

11.

Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors.

Vázquez R, Astorgues-Xerri L, Bekradda M, Gormley J, Buick R, Kerr P, Cvitkovic E, Raymond E, D'Incalci M, Frapolli R, Riveiro ME.

Biochimie. 2015 Jan;108:101-7. doi: 10.1016/j.biochi.2014.10.025. Epub 2014 Nov 5.

PMID:
25446656
12.

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Rabinovich GA, Bieche I, Vidaud M, de Gramont A, Martinet M, Cvitkovic E, Faivre S, Raymond E.

Eur J Cancer. 2014 Sep;50(14):2463-77. doi: 10.1016/j.ejca.2014.06.015. Epub 2014 Jul 16.

PMID:
25042151
13.

Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.

Zucchetti M, Bonezzi K, Frapolli R, Sala F, Borsotti P, Zangarini M, Cvitkovic E, Noel K, Ubezio P, Giavazzi R, D'Incalci M, Taraboletti G.

Cancer Chemother Pharmacol. 2013 Oct;72(4):879-87. doi: 10.1007/s00280-013-2270-2. Epub 2013 Aug 24.

PMID:
23978989
14.

Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells.

Lovejoy KS, Serova M, Bieche I, Emami S, D'Incalci M, Broggini M, Erba E, Gespach C, Cvitkovic E, Faivre S, Raymond E, Lippard SJ.

Mol Cancer Ther. 2011 Sep;10(9):1709-19. doi: 10.1158/1535-7163.MCT-11-0250. Epub 2011 Jul 12.

15.

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.

Serova M, Bieche I, Sablin MP, Pronk GJ, Vidaud M, Cvitkovic E, Faivre S, Raymond E.

Br J Cancer. 2011 Jan 18;104(2):272-80. doi: 10.1038/sj.bjc.6606063. Epub 2010 Dec 21.

16.

ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic.

Nowotnik DP, Cvitkovic E.

Adv Drug Deliv Rev. 2009 Nov 12;61(13):1214-9. doi: 10.1016/j.addr.2009.06.004. Epub 2009 Aug 9. Review.

PMID:
19671439
17.

Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.

Ghoul A, Serova M, Astorgues-Xerri L, Bieche I, Bousquet G, Varna M, Vidaud M, Phillips E, Weill S, Benhadji KA, Lokiec F, Cvitkovic E, Faivre S, Raymond E.

Cancer Res. 2009 May 15;69(10):4260-9. doi: 10.1158/0008-5472.CAN-08-2837. Epub 2009 May 5.

18.

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

Benhadji KA, Serova M, Ghoul A, Cvitkovic E, Le Tourneau C, Ogbourne SM, Lokiec F, Calvo F, Hammel P, Faivre S, Raymond E.

Br J Cancer. 2008 Dec 2;99(11):1808-15. doi: 10.1038/sj.bjc.6604642.

19.

Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells.

Serova M, Ghoul A, Benhadji KA, Faivre S, Le Tourneau C, Cvitkovic E, Lokiec F, Lord J, Ogbourne SM, Calvo F, Raymond E.

Mol Cancer Ther. 2008 Apr;7(4):915-22. doi: 10.1158/1535-7163.MCT-07-2060.

20.

Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.

Serova M, Galmarini CM, Ghoul A, Benhadji K, Green SR, Chiao J, Faivre S, Cvitkovic E, Le Tourneau C, Calvo F, Raymond E.

Br J Cancer. 2007 Sep 3;97(5):628-36. Epub 2007 Jul 17.

21.

A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.

Alexandre J, Kahatt C, Bertheault-Cvitkovic F, Faivre S, Shibata S, Hilgers W, Goldwasser F, Lokiec F, Raymond E, Weems G, Shah A, MacDonald JR, Cvitkovic E.

Invest New Drugs. 2007 Oct;25(5):453-62. Epub 2007 Jul 13.

PMID:
17628744
22.

A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.

Delozier T, Guastalla JP, Yovine A, Levy C, Chollet P, Mousseau M, Delva R, Coeffic D, Vannetzel JM, Zazzi ES, Brienza S, Cvitkovic E.

Anticancer Drugs. 2006 Oct;17(9):1067-73.

PMID:
17001180
23.

Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells.

Voland C, Bord A, Péleraux A, Pénarier G, Carrière D, Galiègue S, Cvitkovic E, Jbilo O, Casellas P.

Mol Cancer Ther. 2006 Sep;5(9):2149-57.

24.

Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.

Paci A, Rezai K, Deroussent A, De Valeriola D, Re M, Weill S, Cvitkovic E, Kahatt C, Shah A, Waters S, Weems G, Vassal G, Lokiec F.

Drug Metab Dispos. 2006 Nov;34(11):1918-26. Epub 2006 Aug 8.

25.

Preclinical and clinical development of novel agents that target the protein kinase C family.

Serova M, Ghoul A, Benhadji KA, Cvitkovic E, Faivre S, Calvo F, Lokiec F, Raymond E.

Semin Oncol. 2006 Aug;33(4):466-78. Review.

PMID:
16890801
26.

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.

Hilgers W, Faivre S, Chieze S, Alexandre J, Lokiec F, Goldwasser F, Raymond E, Kahatt C, Taamma A, Weems G, MacDonald JR, Misset JL, Cvitkovic E.

Invest New Drugs. 2006 Jul;24(4):311-9.

PMID:
16683074
27.

Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.

Mitry E, Ducreux M, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouché O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P.

Gastroenterol Clin Biol. 2006 Mar;30(3):357-63.

28.

Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer.

Petit T, Benider A, Yovine A, Bougnoux P, Spaeth D, Maindrault-Goebel F, Serin D, Tigaud JD, Eymard JC, Simon H, Bertaux B, Brienza S, Cvitkovic E.

Anticancer Drugs. 2006 Mar;17(3):337-43.

PMID:
16520663
29.

A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.

Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, Delva R, Lotz JP, Belle SV, Extra JM, Cvitkovic E.

Ann Oncol. 2006 Mar;17(3):429-36.

PMID:
16500913
30.

Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.

Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E.

Cancer Chemother Pharmacol. 2006 Apr;57(4):491-9. Epub 2005 Aug 2.

PMID:
16075278
31.

Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials.

Raymond E, Kahatt C, Rigolet MH, Sutherland W, Lokiec F, Alexandre J, Tombal B, Elman M, Lee MS, MacDonald JR, Cullen M, Misset JL, Cvitkovic E.

Clin Cancer Res. 2004 Nov 15;10(22):7566-74. Erratum in: Clin Cancer Res. 2005 Feb 15;11(4):1684.

32.

Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.

Alexandre J, Raymond E, Kaci MO, Brain EC, Lokiec F, Kahatt C, Faivre S, Yovine A, Goldwasser F, Smith SL, MacDonald JR, Misset JL, Cvitkovic E.

Clin Cancer Res. 2004 May 15;10(10):3377-85.

33.

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.

Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouché O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P.

Ann Oncol. 2004 Mar;15(3):467-73.

PMID:
14998850
34.

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E, Misset JL.

J Clin Oncol. 2004 Mar 1;22(5):890-9.

PMID:
14990645
35.

Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies.

Mita C, Chatelut E, Bekradda M, Soulié P, Canal P, Misset JL, Cvitkovic E, Bugat R.

Ann Oncol. 2003 Dec;14(12):1776-82.

PMID:
14630684
36.

Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.

Poindessous V, Koeppel F, Raymond E, Cvitkovic E, Waters SJ, Larsen AK.

Int J Oncol. 2003 Nov;23(5):1347-55.

PMID:
14532976
37.

Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.

Droz JP, Muracciole X, Mottet N, Ould Kaci M, Vannetzel JM, Albin N, Culine S, Rodier JM, Misset JL, Mackenzie S, Cvitkovic E, Benoit G.

Ann Oncol. 2003 Aug;14(8):1291-8.

PMID:
12881395
38.

Phase I population pharmacokinetics of irofulven.

Urien S, Alexandre J, Raymond E, Brain E, Smith S, Shah A, Cvitkovic E, Lokiec F.

Anticancer Drugs. 2003 Jun;14(5):353-8.

PMID:
12782941
39.

Cancer of the nasopharynx.

Licitra L, Bernier J, Cvitkovic E, Grandi C, Spinazzé S, Bruzzi P, Gatta G, Molinari R.

Crit Rev Oncol Hematol. 2003 Feb;45(2):199-213. Review.

PMID:
12604130
40.

Cellular and molecular pharmacology of oxaliplatin.

Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E.

Mol Cancer Ther. 2002 Jan;1(3):227-35. Review.

41.

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.

Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, François E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E, de Gramont A.

J Clin Oncol. 2002 Dec 1;20(23):4543-8.

PMID:
12454110
42.

Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.

Wasserman E, Sutherland W, Cvitkovic E.

Clin Colorectal Cancer. 2001 Nov;1(3):149-53. Review.

PMID:
12450427
43.

Exacerbation of oxaliplatin neurosensory toxicity following surgery.

Gornet JM, Savier E, Lokiec F, Cvitkovic E, Misset JL, Goldwasser F.

Ann Oncol. 2002 Aug;13(8):1315-8.

PMID:
12181257
44.

Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences.

Boisdron-Celle M, Craipeau C, Brienza S, Delva R, Guérin-Meyer V, Cvitkovic E, Gamelin E.

Cancer Chemother Pharmacol. 2002 Mar;49(3):235-43. Epub 2002 Jan 16.

PMID:
11935216
45.

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.

Louvet C, André T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A.

J Clin Oncol. 2002 Mar 15;20(6):1512-8.

PMID:
11896099
46.

Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study.

Monnet I, de CH, Soulié P, Saltiel-Voisin S, Bekradda M, Saltiel JC, Brain E, Rixe O, Yataghene Y, Misset JL, Cvitkovic E.

Ann Oncol. 2002 Jan;13(1):103-7.

PMID:
11863089
47.

A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.

van Kesteren C, Mathĵt RA, López-Lázaro L, Cvitkovic E, Taamma A, Jimeno JM, Guzman C, Schellens JH, Misset JL, Brain E, Hillebrand MJ, Rosing H, Beijnen JH.

Cancer Chemother Pharmacol. 2001 Dec;48(6):459-66.

PMID:
11800026
48.

Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.

Sparidans RW, Rosing H, Hillebrand MJ, López-Lázaro L, Jimeno JM, Manzanares I, van Kesteren C, Cvitkovic E, van Oosterom AT, Schellens JH, Beijnen JH.

Anticancer Drugs. 2001 Sep;12(8):653-66.

PMID:
11604552
49.

[Oxaliplatin: a first DACH-platinum in oncology].

Laadem A, Cvitkovic E.

Bull Cancer. 2001 Aug;88 Spec No:S9-13. Review. French.

50.

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.

Bensmaïne MA, Marty M, de Gramont A, Brienza S, Lévi F, Ducreux M, François E, Gamelin E, Bleiberg H, Cvitkovic E.

Br J Cancer. 2001 Aug 17;85(4):509-17.

Supplemental Content

Loading ...
Support Center